What is Vabysmo (faricimab-svoa) for?
Buy Vabysmo (faricimab-svoa): Vabysmo (faricimab-svoa) is a treatment for two eye diseases. It works by stopping the growth of new blood vessels in the eye. This helps to improve vision.
- Neovascular or “wet” age-related macular degeneration (nAMD)
- Diabetic macular edema (DME)
It comes in a single-dose vial with 120 mg/mL faricimab-svoa.
H0w does Vabysmo (faricimab-svoa) work?
Neovascular and diabetic macular edema cause vision loss. These diseases are linked to proteins called angiopoietin-2 and VEGF-A. They make blood vessels unstable, leading to vision problems.
Vabysmo’s active ingredient, faricimab-svoa, is a special antibody. It blocks these proteins, helping to keep blood vessels stable. This can improve and maintain vision.
Where has Vabysmo (faricimab-svoa) been approved?
Vabysmo (faricimab-svoa) is approved for treating eye diseases in the USA. It was approved by:
- The Food and Drug Administration (FDA), USA on January 28, 2021.
This medicine might also be approved in other places. If you have questions, contact our support team.
How is Vabysmo (faricimab-svoa) taken?
The first 4 doses are 6 mg, given every 4 weeks. After that, the schedule is based on how the patient responds.
Vabysmo should not be used during pregnancy unless it’s really needed. This is to protect the unborn baby.
For more details on dosage and how to use Vabysmo, see the official prescribing information. Note: Always talk to your doctor for the right dosage.
Are there any known adverse reactions or side effects of Vabysmo (faricimab-svoa)?
Common adverse reactions
The most common side effects are:
- Conjunctival hemorrhage
Serious adverse reactions
Some serious side effects include:
- Hypersensitivity
- Endophthalmitis and retinal detachments
- Increase in intraocular pressure
- Thromboembolic events
For a full list of side effects, see the official prescribing information.